HAEMONETICS CORP — Director's Dealing 2013

Apr 5, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-04-03

Reporting Person: ALLEN PETER M (President, Global Plasma)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-04-03	Common Stock	M	22828.0	$10.73	Acquired	49174	Direct
2013-04-03	Common Stock	S	22828.0	$41.4405	Disposed	26346	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-04-03	Non-Qualified Stock Option (right to buy)	$10.73	M	22828.0	Disposed	2013-09-03	Common Stock (22828)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$13.0525	2014-05-05	Common Stock (30000)	30000	Direct
Non-Qualified Stock Option (right to buy)	$25.535	2014-10-24	Common Stock (36426)	36426	Direct
Non-Qualified Stock Option (right to buy)	$26.47	2016-10-27	Common Stock (31340)	31340	Direct
Non-Qualified Stock Option (right to buy)	$27.275	2015-10-22	Common Stock (30494)	30494	Direct
Non-Qualified Stock Option (right to buy)	$27.495	2017-10-27	Common Stock (30776)	30776	Direct
Non-Qualified Stock Option (right to buy)	$30.67	2018-10-25	Common Stock (30740)	30740	Direct
Non-Qualified Stock Option (right to buy)	$39.055	2019-10-24	Common Stock (32192)	32192	Direct

Footnotes

F1: Pursuant to a 10b5-1 Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.